论文部分内容阅读
目的探讨罗格列酮治疗2型糖尿病的临床疗效。方法选取新疆塔城地区人民医院2014年2月—2015年2月收治的2型糖尿病患者102例,按随机数字表法将患者分成研究组与对照组,各51例。对照组患者予以瑞格列奈治疗,研究组予以罗格列酮治疗,比较两组患者的空腹血糖(FBG)、餐后2h血糖(2h PG)、糖化血红蛋白(HbA_(1c))、胰岛素抵抗指数(IRI)及临床疗效。结果治疗前两组FBG、2hPG、HbA_(1c)、IRI比较,差异无统计学意义(P>0.05);治疗后两组FBG、2h PG、Hb A1c、IRI比较,差异有统计学意义(P<0.05)。研究组患者总有效率(94.1%)高于对照组(78.4%),差异有统计学意义(P<0.05)。结论罗格列酮治疗2型糖尿病可有效改善患者的血糖与胰岛素水平,且疗效确切。
Objective To investigate the clinical efficacy of rosiglitazone in the treatment of type 2 diabetes mellitus. Methods Totally 102 patients with type 2 diabetes who were admitted to Tacheng District People’s Hospital of Xinjiang from February 2014 to February 2015 were randomly divided into study group and control group with 51 cases in each group. The patients in the control group were treated with repaglinide. The study group was treated with rosiglitazone. The fasting blood glucose (FBG), 2h PG, HbA_ (1c), insulin resistance Index (IRI) and clinical efficacy. Results There were no significant differences in FBG, 2hPG, HbA 1c and IRI between the two groups before treatment (P> 0.05). There was significant difference in FBG, 2h PG, Hb A1c and IRI between the two groups after treatment <0.05). The total effective rate (94.1%) in the study group was higher than that in the control group (78.4%), the difference was statistically significant (P <0.05). Conclusion Rosiglitazone treatment of type 2 diabetes patients can effectively improve blood glucose and insulin levels, and the exact effect.